Compare ATEN & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | PHAT |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2014 | 2019 |
| Metric | ATEN | PHAT |
|---|---|---|
| Price | $20.60 | $11.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $22.67 | $17.33 |
| AVG Volume (30 Days) | 921.6K | ★ 928.9K |
| Earning Date | 02-04-2026 | 03-05-2026 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $290,557,000.00 | $147,190,000.00 |
| Revenue This Year | $9.40 | $221.87 |
| Revenue Next Year | $7.65 | $80.37 |
| P/E Ratio | $36.32 | ★ N/A |
| Revenue Growth | 11.03 | ★ 460.30 |
| 52 Week Low | $13.81 | $2.21 |
| 52 Week High | $21.90 | $18.31 |
| Indicator | ATEN | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 66.40 | 38.10 |
| Support Level | $20.17 | $11.83 |
| Resistance Level | $21.31 | $13.17 |
| Average True Range (ATR) | 0.78 | 0.74 |
| MACD | 0.29 | -0.08 |
| Stochastic Oscillator | 79.60 | 21.85 |
A10 Networks Inc is a provider of security and infrastructure solutions for on-premises, hybrid cloud, and edge-cloud environments of its multinational enterprise, communication, cloud and web service provider customers who strive to provide business-critical applications and networks that are secure, available, and efficient. As cyber-attacks increase in volume and complexity, the company integrates security and artificial intelligence (AI) enabled capabilities in its solutions that enable its customers to continue to adapt to market trends in hybrid cloud, AI-ready data centers and the ever-increasing need for high-performance, high availability and low latency. The company generates the maximum of its revenue from Americas.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.